Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Aug 12, 2016 04:37PM Form 4 Loxo Oncology, Inc. For: Aug 10 Filed by: ORBIMED ADVISORS LLC
Aug 12, 2016 04:26PM Form SC 13D/A Loxo Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 10, 2016 03:39PM ORIC Pharmaceuticals Appoints Ashraf Hanna, PhD, MD, as Chief Executive Officer, and Darcy Mootz, PhD, as Chief Business Officer
Aug 8, 2016 04:30PM Lion Biotechnologies Announces Second Quarter 2016 Financial Results
Aug 8, 2016 07:30AM Cleave Biosciences Raises $37 Million Series B Financing
Aug 5, 2016 05:17PM Form SC 13D/A Loxo Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 5, 2016 04:06PM Form 4 GLAUKOS Corp For: Aug 03 Filed by: ORBIMED ADVISORS LLC
Aug 4, 2016 04:09PM Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Jul 28, 2016 04:56PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
Jul 27, 2016 09:00AM Avitide, Inc., to Expand Affinity Separation Discovery and Manufacturing Operations
Jul 26, 2016 06:05PM Form 4 Relypsa Inc For: Jul 22 Filed by: ORBIMED ADVISORS LLC
Jul 26, 2016 04:15PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
Jul 25, 2016 05:08PM Form 4 Audentes Therapeutics, For: Jul 25 Filed by: ORBIMED ADVISORS LLC
Jul 12, 2016 02:36PM Form SC 13D/A PIERIS PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Jul 8, 2016 04:13PM Form SC 13G/A Cynapsus Therapeutics Filed by: ORBIMED ADVISORS LLC
Jul 7, 2016 04:20PM Form SC 13D SELECTA BIOSCIENCES INC Filed by: ORBIMED ADVISORS LLC
Jun 30, 2016 04:01PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 29, 2016 04:50PM Form 4 SELECTA BIOSCIENCES INC For: Jun 27 Filed by: ORBIMED ADVISORS LLC
Jun 21, 2016 04:15PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 21, 2016 08:33AM Positive Patient Outcomes Data on Inspire Therapy Highlighted at SLEEP 2016
Jun 20, 2016 05:41PM Form 4 RESPONSE BIOMEDICAL CORP For: Jun 16 Filed by: OrbiMed Advisors Ltd
Jun 20, 2016 05:14PM Form SC 13D/A RESPONSE BIOMEDICAL CORP Filed by: ORBIMED ADVISORS LLC
Jun 17, 2016 07:32PM Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
Jun 17, 2016 01:35PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 16, 2016 06:00PM Form 4 Corvus Pharmaceuticals, For: Jun 14 Filed by: ORBIMED ADVISORS LLC
Jun 16, 2016 03:30AM Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement
Jun 13, 2016 05:18PM Form 4 Corvus Pharmaceuticals, For: Jun 09 Filed by: ORBIMED ADVISORS LLC
Jun 13, 2016 08:30AM Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Jun 9, 2016 02:55PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 7, 2016 04:52PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 3, 2016 05:23PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
Jun 3, 2016 12:55PM Unusual 11 Mid-Day Movers 6/3: (LBIO) (EBIO) (JVA) Higher; (GSAT) (GOGO) (IMMU) Lower
Jun 3, 2016 09:36AM Lion Biotechnologies (LBIO) Names Maria Fardis, Ph.D., as CEO; Board Appointments Announced
Jun 3, 2016 09:34AM Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO
Jun 3, 2016 09:00AM Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer
May 24, 2016 04:38PM Form 4 Corvus Pharmaceuticals, For: May 20 Filed by: ORBIMED ADVISORS LLC
May 20, 2016 05:22PM Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: ORBIMED ADVISORS LLC
May 20, 2016 04:07PM Form SC 13D Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 16, 2016 04:45PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 13, 2016 05:10PM Form 4 Intellia Therapeutics, For: May 11 Filed by: ORBIMED ADVISORS LLC
May 2, 2016 08:00AM Graybug Vision Announces $44.5 Million Series B Financing
Apr 27, 2016 08:00AM Critical Outcome Technologies Augments Advisory Board Drug Development Experience
Apr 19, 2016 05:54PM Xtent, Inc. (XTNT) Prelim. Q1 Rev. Misses Consensus
Apr 19, 2016 05:50PM Xtant Medical Pre-Announces First Quarter 2016 Revenue
Apr 19, 2016 05:02PM Form 3 Aeglea BioTherapeutics, For: Apr 12 Filed by: ORBIMED ADVISORS LLC
Apr 18, 2016 03:25PM Form SC 13G Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
Apr 13, 2016 10:21AM Form SC 13G/A Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
Apr 12, 2016 04:21PM Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
Apr 1, 2016 01:11PM Form SC 13D Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Mar 31, 2016 04:45PM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed